1-12-diamino-3-6-9-triazadodecane and Psychotic-Disorders

1-12-diamino-3-6-9-triazadodecane has been researched along with Psychotic-Disorders* in 1 studies

Other Studies

1 other study(ies) available for 1-12-diamino-3-6-9-triazadodecane and Psychotic-Disorders

Article	Year
Do users of risperidone who switch brands because of generic reference pricing fare better or worse than non-switchers? A New Zealand natural experiment. Administration and policy in mental health, 2015, Volume: 42, Issue:6 This study evaluated patient health outcomes and any impact on healthcare costs consequent to the implementation of generic reference-pricing of risperidone in New Zealand using national datasets. Reference pricing risperidone reduced the price of the originator brand by 50 % as well as overall expenditure on risperidone tablets. Half of all patients made a single switch to generic risperidone, with the remainder making multiple switches between brands. 1.5 % made a switch-back to the originator brand. No difference was found in use of healthcare services between switchers and non-switchers of the originator brand or versus the comparator group. This refutes the available literature on brand-to-generic and generic-to-generic switching. Topics: Aged; Antipsychotic Agents; Cohort Studies; Drug Costs; Drug Substitution; Drugs, Generic; Female; Humans; Male; Mental Health Services; Middle Aged; New Zealand; Psychotic Disorders; Retrospective Studies; Risperidone; Spermine; Treatment Outcome	2015

Article

Year

Do users of risperidone who switch brands because of generic reference pricing fare better or worse than non-switchers? A New Zealand natural experiment.

Administration and policy in mental health, 2015, Volume: 42, Issue:6

This study evaluated patient health outcomes and any impact on healthcare costs consequent to the implementation of generic reference-pricing of risperidone in New Zealand using national datasets. Reference pricing risperidone reduced the price of the originator brand by 50 % as well as overall expenditure on risperidone tablets. Half of all patients made a single switch to generic risperidone, with the remainder making multiple switches between brands. 1.5 % made a switch-back to the originator brand. No difference was found in use of healthcare services between switchers and non-switchers of the originator brand or versus the comparator group. This refutes the available literature on brand-to-generic and generic-to-generic switching.

Topics: Aged; Antipsychotic Agents; Cohort Studies; Drug Costs; Drug Substitution; Drugs, Generic; Female; Humans; Male; Mental Health Services; Middle Aged; New Zealand; Psychotic Disorders; Retrospective Studies; Risperidone; Spermine; Treatment Outcome

2015